Supplemental Figure S5.

Indices of disease severity in mice after bleomycin challenge with vascular endothelial growth factor receptor (VEGFR) blockade. A: Kaplan-Meier survival curves for untreated controls and for 14 days after bleomycin administration with concurrent control IgG, VEGFR-3 blockade by mF4-31C1, and/or VEGFR-2 blockade by DC101 in C57BL/6 mice showing significantly greater mortality after bleomycin with VEGFR-2 blockade versus control IgG group). B and C: Comparison of bronchoalveolar lavage fluid (BALF) protein and leukocytes at 14 days after bleomycin challenge without or with inhibition of VEGFR-3 (mF4-31C1) and/or VEGFR-2 (DC101). BALF leukocytes were significantly more numerous in all groups after bleomycin treatment than in the baseline group and were also more numerous after bleomycin plus DC101 than bleomycin plus IgG. D: Significantly more α-smooth muscle actin staining (area density) in lungs after bleomycin plus IgG and even more after bleomycin plus DC101. In all panels, groups indicated by colors: blue, baseline (no bleomycin); and 14-day bleomycin + treatment with: black, control IgG; red, DC101 + mF4-31C1 combination; magenta, DC101; green, mF4-31C1. n = 4 to 14 mice per group (D). ∗P < 0.05 versus control IgG group (log-rank test; A); ∗P < 0.05 versus baseline (analysis of variance; B–D); ^†P < 0.05 versus bleomycin plus IgG (analysis of variance).